JP2021532113A5 - - Google Patents

Info

Publication number
JP2021532113A5
JP2021532113A5 JP2021503578A JP2021503578A JP2021532113A5 JP 2021532113 A5 JP2021532113 A5 JP 2021532113A5 JP 2021503578 A JP2021503578 A JP 2021503578A JP 2021503578 A JP2021503578 A JP 2021503578A JP 2021532113 A5 JP2021532113 A5 JP 2021532113A5
Authority
JP
Japan
Prior art keywords
disorders
compound
formula
diseases
release system
Prior art date
Application number
JP2021503578A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020020789A5 (https=
JP2021532113A (ja
Filing date
Publication date
Priority claimed from US16/043,567 external-priority patent/US10905667B2/en
Application filed filed Critical
Priority claimed from PCT/EP2019/069561 external-priority patent/WO2020020789A1/de
Publication of JP2021532113A publication Critical patent/JP2021532113A/ja
Publication of JP2021532113A5 publication Critical patent/JP2021532113A5/ja
Publication of JPWO2020020789A5 publication Critical patent/JPWO2020020789A5/ja
Pending legal-status Critical Current

Links

JP2021503578A 2018-07-24 2019-07-19 経口投与可能であり、放出を修飾した薬学的投薬形態 Pending JP2021532113A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18185127 2018-07-24
US16/043,567 US10905667B2 (en) 2018-07-24 2018-07-24 Orally administrable modified-release pharmaceutical dosage form
US16/043,567 2018-07-24
EP18185127.0 2018-07-24
PCT/EP2019/069561 WO2020020789A1 (de) 2018-07-24 2019-07-19 Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung

Publications (3)

Publication Number Publication Date
JP2021532113A JP2021532113A (ja) 2021-11-25
JP2021532113A5 true JP2021532113A5 (https=) 2022-07-26
JPWO2020020789A5 JPWO2020020789A5 (https=) 2022-07-26

Family

ID=67314781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503578A Pending JP2021532113A (ja) 2018-07-24 2019-07-19 経口投与可能であり、放出を修飾した薬学的投薬形態

Country Status (22)

Country Link
EP (1) EP3826627B1 (https=)
JP (1) JP2021532113A (https=)
KR (1) KR20210035235A (https=)
CN (1) CN112469402B (https=)
AU (1) AU2019311234A1 (https=)
BR (1) BR112020026644A2 (https=)
CA (1) CA3107169A1 (https=)
CL (1) CL2021000160A1 (https=)
CO (1) CO2021000450A2 (https=)
CR (1) CR20210043A (https=)
DO (1) DOP2021000015A (https=)
EC (1) ECSP21003707A (https=)
IL (1) IL280083A (https=)
JO (1) JOP20210019A1 (https=)
MA (1) MA53368A (https=)
MX (1) MX2021000904A (https=)
PE (1) PE20210415A1 (https=)
PH (1) PH12021550170A1 (https=)
SG (1) SG11202100369WA (https=)
TW (1) TW202019402A (https=)
UY (1) UY38308A (https=)
WO (1) WO2020020789A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020245342A1 (en) 2019-06-07 2020-12-10 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
US20240317696A1 (en) * 2021-05-14 2024-09-26 Medshine Discovery Inc. Alkyl carboxylic acid compounds and application thereof
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
CN117982443B (zh) * 2022-10-31 2026-03-06 优辉药业(北京)有限公司 一种达格列净二甲双胍缓释片剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
ES2039287T3 (es) 1987-01-14 1993-09-16 Ciba-Geigy Ag Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles.
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) * 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2019105881A1 (de) 2017-12-01 2019-06-06 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropansäure und dessen kristalline form für die verwendung als pharmazeutischer wirkstoff

Similar Documents

Publication Publication Date Title
JP2021532113A5 (https=)
CN112469402B (zh) 可口服给药且缓释的药物剂型
JP2019048830A (ja) 複素環式化合物及びそれらの使用
KR101841662B1 (ko) 프로톤 펌프 저해제의 고체분산체 및 이를 포함하는 약제학적 조성물
US20210113504A1 (en) Orally administrable modified-release pharmaceutical dosage form
US20200237648A1 (en) Orally administrable modified-released pharmaceutical dosage form
JP2021531297A5 (https=)
JPWO2020020789A5 (https=)
CN107018650B (zh) 包含氨氯地平和氯沙坦的固体药物组合物
WO2020020790A1 (de) Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
TWI720115B (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物的製備方法
KR20200021774A (ko) 시타글립틴 속방층을 포함하는 제제의 제조방법, 상기 제조방법으로 제조된 제제, 시타글립틴 속방층 코팅 방법, 및 시타글립틴 속방층 코팅용 조성물
JPWO2020020790A5 (https=)
CN110237072B (zh) 药物组合物的制备方法
EP3378478B1 (en) Pharmaceutical composition comprising quinoline derivative or salt thereof
HK40041248A (en) Pharmaceutical dosage form which can be administered orally and has modified release
JPWO2023051490A5 (https=)
JP2003504404A (ja) 抗虚血薬
CN110237071B (zh) 药物制剂及其应用
CN101897675B (zh) 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
KR20180054527A (ko) 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합제제
WO2016009314A1 (en) "amorphous mixture of ivabradine and chrysin"
WO2005051374A1 (en) Tablets of citalopram hydrobromide
TW201127420A (en) Oral pharmaceutical composition containing Valsartan, Valsartan and Hydrochlorothiazide, Valsartan and Amlodipine or Valsartan, Hydrochlorothiazide and Amlodipine